Cambridge University intends to start clinical trials of its vaccine against coronavirus in autumn as the British government provided 1.9 million pounds sterling financing, as the university reported.
“A Cambridge-developed vaccine candidate against SARS-CoV-2 could begin clinical trials in the UK in late autumn or early next year, thanks to a £1.9million award from the UK government,” the message said.
The scientists who developed the vaccine stated that their approach that uses genetic sequences of all known coronaviruses for sharpening of the immune response might help to avoid side effects from the hyper-inflammatory immune responses.
Thus, the Cambridge vaccine, DIOS-CoVax2, is based on DNA. The structures of the antigens are coded by synthetic genes that might reprogram the immune system to produce antibodies against the coronavirus.
Moreover, the university showed that this method of DNA-vector is safe and effective for stimulating an immune response against other pathogens in multiple phases. Besides, it can be used without needles and it may simplify the widespread of the vaccine.
On August 11, President of Russia Vladimir Putin reported that the first vaccine against coronavirus was registered in Russia.
It is noted that the vaccine would be produced by N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology and Russian Binnopharm Company. According to Murashko, finalizing takes place of the technical regulations for scaling of production at the number of Russian productions.
Later, China reported registering its first vaccine against coronavirus. It is stated that the application for the patent was filed in March but it was approved only now. The patent is issued by the National Intellectual Property Administration.